USPTO serial 87543606
LIVZON
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 17, 2018
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.
Need help with LIVZON?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Livzon Pharmaceutical Group Inc.
Guangdong Province, CN
Livzon Pharmaceutical Group Inc.
Guangdong Province, CN
Livzon Pharmaceutical Group Inc.
Guangdong Province, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicholas D. Wells
Nicholas D. Wells Legends Law Group, PLLC330 Main StKaysville, UT 84037United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the treatment of gastrointestinal diseases, for human purposes; [ Pharmaceutical products for the prevention and treatment of cancer, for human purposes; Tumor suppressing agents, for human purpose; ] Antibacterial pharmaceuticals; [ Cardiovascular pharmaceuticals; ] Pharmaceuticals, namely, anti-infectives; [ Medical preparations for slimming purposes; Food for babies; Bulk drugs, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Bulk drug in the nature of a pharmaceutical preparation for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cardiovascular disease, hypertension, alzheimer disease, depression, cancer, diabetes, lung disease, liver disease, cerebral ischemia, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; Chinese medicine nostrum in the nature of natural remedy preparations for the treatment of cancer; Antibiotics; Biochemical medicines for the treatment of pneumonia, urinary tract infection, gynecological infections, skin and skin structure infections, meningitis, septicemia, cancer, diabetes, prostate disease, Infertility, rheumatoid arthritis, immune system disease, and gastrointestinal disease; ] Biochemical drugs for treatment of gastrointestinal diseases [ ; Blood products, namely, immunoglobulins for medical or clinical use; Blood products for medical purposes, namely, blood plasma, reagent blood cells; Blood products for medical purposes, namely, blood plasma products, red blood cell products, and leukocyte products; Dietetic foods adapted for medical use; Dietetic beverages adapted for medical purposes ] | ACTIVE | — |
| 010 | [ Medical apparatus for detecting cancer; Medical device for treating cancer; Medical apparatus and instruments for use in surgery; Medical device and surgical instrument for use in diagnosis and surgery of the gastro-intestinal tract; Ultrasound diagnostic apparatus; X-ray diagnostic apparatus; Dental instruments, namely, oral irrigators; Drills for dental applications; Orthodontic machines and instruments, for dental purposes; Weight lifting machines for physical therapy; Foam rollers for use in physical therapy; Manually-operated exercise equipment for physical therapy purposes; Hearing aids; Baby bottles; Contraceptive apparatus, non-chemical; Artificial limbs; Orthopaedic belts; Orthopaedic knee bandages; Orthopaedic hip prostheses; Sanitary masks for medical purposes; Gloves for medical purposes ] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Livzon Pharmaceutical Group Inc.
- Other trademarks owned by Livzon Pharmaceutical Group Inc.
- Other trademarks owned by Livzon Pharmaceutical Group Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named LIVZON
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 5, 2025 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Mar 5, 2025 | 8.PR | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | — |
| Mar 5, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 3, 2024 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Jul 17, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 21, 2019 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 17, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 1, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 1, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 11, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 23, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 9, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 9, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 9, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 9, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 3, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 26, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 1, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 31, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 29, 2017 | NWAP | NEW APPLICATION ENTERED | — |